The Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Alexion Pharmaceuticals, Inc. Investors and Encourages Investors to Contact the Firm

BENSALEM, Pa.--(BUSINESS WIRE)--

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Alexion Pharmaceuticals, Inc. ("Alexion" or the "Company") ALXN securities between February 10, 2014 and November 9, 2016, inclusive (the "Class Period"). Alexion investors have until January 17, 2017 to file a lead plaintiff motion.

Investors suffering losses on their Alexion investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com.

According to the Complaint filed in this lawsuit, Alexion made false and/or misleading statements and/or failed to disclose: (1) that Alexion employed improper sales practices with respect to its product Soliris; (2) that the Company's revenues from Soliris sales were unlikely to be sustainable; and (3) that, as a result of the above, Alexion's public statements were materially false and misleading at all relevant times.

If you purchased shares of Alexion during the Class Period you may move the Court no later than January 17, 2017 to ask the Court to appoint you as lead plaintiff. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at http://www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161207006077/en/